An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

Trial Profile

An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Apitolisib (Primary) ; Ketoconazole
  • Indications Advanced breast cancer; Endometrial cancer; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Jul 2012 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top